Pliant Therapeutics Financials - Benzinga

Pliant Therapeutics Inc

PLRXNASDAQ

Trade with Public

Trade with Public

$1.05

Last update: Aug 6, 4:21 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Pliant Therapeutics Financials

Pliant Therapeutics (PLRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Pliant Therapeutics Q1 EPS $(0.32) Beats $(0.35) Estimate

Benzinga Newsdesk

PRO
Pliant Therapeutics Q4 EPS $(0.38) Beats $(0.41) Estimate

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.77 percent. This is a 53.66 percent increase over losses of $(0.82) per share

Benzinga Newsdesk

PRO
Pliant Therapeutics Q3 EPS $(0.43) Beats $(0.52) Estimate

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 54.74 percent increase over losses of $(0.95) per share

Benzinga Newsdesk

PRO
Pliant Therapeutics Q2 EPS $(0.71), Inline

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.71) per share which met the analyst consensus estimate. This is a 22.83 percent increase over losses of $(0.92) per share from the same period last year.

Benzinga Newsdesk

PRO
Pliant Therapeutics Q1 EPS $(0.92) Misses $(0.74) Estimate

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.74) by 24.32 percent. This is a 17.95 percent decrease over losses of $(0.78) per share

Benzinga Newsdesk

PRO
Pliant Therapeutics Q4 2024 GAAP EPS $(0.82) Beats $(0.98) Estimate

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.98) by 16.33 percent. This is a 18.84 percent decrease over losses of $(0.69) per share

Benzinga Newsdesk